Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

China Pharma Holdings (CPHI) Receivables - Net (2016 - 2025)

China Pharma Holdings' Receivables - Net history spans 16 years, with the latest figure at $241412.0 for Q4 2025.

  • For Q4 2025, Receivables - Net fell 98.25% year-over-year to $241412.0; the TTM value through Dec 2025 reached $241412.0, down 98.25%, while the annual FY2025 figure was $241412.0, 98.25% down from the prior year.
  • Receivables - Net reached $241412.0 in Q4 2025 per CPHI's latest filing, down from $294514.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $14.3 million in Q4 2023 to a low of $44444.0 in Q3 2022.
  • Average Receivables - Net over 5 years is $3.7 million, with a median of $414162.5 recorded in 2021.
  • Peak YoY movement for Receivables - Net: skyrocketed 15115.77% in 2024, then crashed 98.25% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $714475.0 in 2021, then plummeted by 41.0% to $421531.0 in 2022, then skyrocketed by 3290.15% to $14.3 million in 2023, then decreased by 3.3% to $13.8 million in 2024, then plummeted by 98.25% to $241412.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Receivables - Net are $241412.0 (Q4 2025), $294514.0 (Q3 2025), and $268793.0 (Q2 2025).